NOVELLI, Mauro

NOVELLI, Mauro  

SCIENZE MEDICHE  

Mostra records
Risultati 1 - 20 di 171 (tempo di esecuzione: 0.032 secondi).
Titolo Data di pubblicazione Autore(i) File
'Aleukemic' granulomatous leukemia cutis. 1998 TOMASINI C ;QUAGLINO P ;NOVELLI M ;FIERRO MT
[Heterogenicity of T-cell cutaneous lymphomas: pleomorphic lymphoma of intermediate phenotype between the thymic and post-thymic stages. Study of 2 cases] 1987 BERNENGO MG ;MUSSO L ;NOVELLI M ;DOVEIL GC
[Role of immediate hypersensitivity in immune complex deposits: the platelet activating factor] 1978 CAMUSSI G ;RAGNI R ;NOVELLI M ;BOSIO D
[Serum levels of soluble receptors of interleukin-2 in skin pathology] 1990 MASSOBRIO R ;LISA F ;NOVELLI M ;BERNENGO MG
Abstract 5603: Melanoma PD1 expression is upregulated by MAPK inhibitors leading to an immune-independent synergism with anti-PD1 antibodies 2017 Sanlorenzo, Martina; Vujic, Igor; Floris, Arianna; Novelli, Mauro; Donini, Chiara; Gammaitoni, Loretta; Giraudo, Lidia; Macagno, Marco; Quaglino, Pietro; Fierro, Maria Teresa; Giordano, Silvia; Carnevale-Schianca, Fabrizio; Aglietta, Massimo; Sangiolo, Dario
Adhesion molecules in lymphomatoid granulomatosis 1994 SAVOIA P; M. NOVELLI; BERTERO M; BERNENGO MG
Adjuvant therapy of stage IIIb melanoma with interferon alfa-2b: clinical and immunological relevance 1995 DOVEIL GC; FIERRO MT; M. NOVELLI; APPINO A; BERTERO M; QUAGLINO P; BERNENGO MG
Alemtuzumab for the treatment of Sézary sindrome: clinical and immunological findings in 10 patients. 2006 Bernengo MG; Quaglino P; Comessatti A; Ortoncelli M; Novelli M; Fierro MT.
Alterazioni funzionali e fenotipiche dei polimorfonucleati nei pazienti affetti da dermatite atopica 2011 Banche G; Allizond V; Novelli M; Fierro MT; Mandras N; Murabito P; Quaglino P; Scalas D; Merlino C; Roana J; Tullio V; Bernengo MG; Cuffini AM
Alterazioni funzionali e fenotipiche dei polimorfonucleati nella sindrome di sezary 2009 G. Banche; M.T. Fierro; M. Novelli; V. Allizond; A. Comessatti; P. Quaglino; D. Scalas; C. Merlino; M.G. Bernengo; A Cuffini
Atypical mononuclear cells in “Neutrophilic Dermatitis” 1998 Tomasini C; Aloi F; Osella-Abate S; Novelli M
Blood Flow Cytometry in Sézary Syndrome: New Insights on Prognostic Relevance and Immunophenotypic Changes During Follow-up. 2015 Novelli M; Fava P; Sarda C; Ponti R; Osella-Abate S; Savoia P; Bergallo M; Lisa F; Fierro MT; Quaglino P.
BRAF and MEK inhibitors increase PD1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD1 antibody 2018 Sanlorenzo, Martina; Vujic, Igor; Floris, Arianna; Novelli, Mauro; Gammaitoni, Loretta; Giraudo, Lidia; Macagno, Marco; Leuci, Valeria; Rotolo, Ramona; Donini, Chiara; Basiricò, Marco; Quaglino, Pietro; Fierro, Maria Teresa; Giordano, Silvia; Sibilia, Maria; Carnevale-Schianca, Fabrizio; Aglietta, Massimo; Sangiolo, Dario
Bullous pemphigoid is characterised by a reduction of skin-homing/circulating FOXP3+ Tregs and by a down-regulation of the IL-10 pathway 2012 Quaglino P; Antiga E; Novelli M; Nardò T; Fava P; Ponti R; Osella-Abate S; Caproni M; Fabbri P; Bernengo MG
Bullous, cutaneous, pleomorphic T-cell Lymphoma: analysis of integrins and extracellular matrix components. 1996 SAVOIA P; NOVELLI M; FIERRO MT; BERNENGO MG
CD26 (DPP-IV)- A useful marker in Sezary sindrome 1994 Novelli M; Fierro MT; Quaglino P; Lisa F; Doveil GC; Bernengo MG
CD26 expression on cutaneous infiltrates from patients CD26 expression on cutaneous infiltrates from patients with cutaneous T-cell lymphoma (CTCL) CD26 in cutaneous T-cell lymphoma patients. 2003 Novelli M; Comessatti A;Quaglino P;Savoia P; Fierro MT; Bernengo MG.
CD26 expression on keratinocytes in normal skin, inflammatory skin diseases and cutaneous T-cell lymphomas (CTCL). 1995 Savoia P; Fierro MT; Novelli M; Verrone A; Quaglino P; Bernengo MG
CD26 expression on keratinocytes in normal skin, inflammatory skin diseases and cutaneous T-cell lymphomas (CTCL). 1995 Savoia P; Fierro MT; Novelli M; Verrone A; Quaglino P; Bernengo MG
CD3-CD56+ primary pure cutaneous lymphoma: a distinct entity in the spectrum of CD56 malignancies. 1996 Savoia P; Fierro MT; Novelli M; Verrone A; Quaglino P; Bernengo MG